Clinical AI platform to be trained on 30 years of NEJM archives

© Suriyo - stock.adobe.com

OpenEvidence, an artificial intelligence (AI)-driven clinical decision support platform, has secured a $1 billion valuation following a Series A funding round led by Sequoia Capital. The investment marks the company’s first institutional funding, bringing its total capital raised to more than $100 million. The funding will support OpenEvidence’s expansion and enhance its AI-powered copilot for physicians through a newly announced content partnership with the New England Journal of Medicine (NEJM) Group.

Under the multi-year agreement, OpenEvidence will integrate published content and multimedia from NEJM and its affiliated publications — NEJM Evidence, NEJM AI, NEJM Catalyst and NEJM Journal Watch — dating back to 1990. The partnership enables OpenEvidence’s AI models to leverage decades of peer-reviewed medical research, positioning the platform as a valuable resource for physicians at the point of care.

“In serving clinicians, it is crucial that the trusted evidence we publish informs clinical decisions,” said David Sampson, vice president and chief publishing officer of NEJM Group. “OpenEvidence is emerging as a preferred resource for many clinicians. We are delighted to support OpenEvidence as a content partner and look forward to further collaborating to improve the delivery of clinical knowledge.”

Founded in 2023, OpenEvidence has rapidly grown into one of the most widely used AI platforms in healthcare, with hundreds of thousands of verified physicians using it across more than 10,000 care centers in the United States. According to the company, 40,000 new verified doctors register each month, making it one of the fastest-growing medical technology platforms.

The company’s proprietary AI copilot is designed to support clinicians by synthesizing and delivering evidence-based insights in real time, addressing the increasing complexity of modern medical knowledge. The AI assists physicians in assessing drug efficacy, evaluating treatment effects on patients with specific comorbidities, analyzing safety profiles, and determining risks of discontinuing medications.

“As we approach our platform’s two-year anniversary later this spring, OpenEvidence is trusted and used daily by hundreds of thousands of doctors. But we’re just getting started,” said Daniel Nadler, founder of OpenEvidence. “Our Series A with Sequoia will enable OpenEvidence to continue building the most trusted AI platform for doctors and other medical professionals worldwide.”

The integration of NEJM’s archives into OpenEvidence’s AI models comes at a time when medical knowledge is doubling approximately every 73 days, making it increasingly difficult for physicians to stay current.

OpenEvidence’s AI is trained specifically for medical professionals and is free for verified U.S. physicians.

The company plans to use its latest funding to expand its team of AI scientists, many from Harvard and the Massachusetts Institute of Technology (MIT), and to develop medical domain-specific Large Language Models (LLMs) designed for clinical applications.

Pat Grady, partner at Sequoia Capital, emphasized the investment’s potential impact on healthcare.

“As growing caseloads and patient demands make it nearly impossible for doctors to stay current and deliver the best care, OpenEvidence is the solution physicians have been yearning for,” Grady said. “The scale of OpenEvidence’s life-saving impact is massive, positioning it to become one of the most important companies of the next decade.”

Beyond its NEJM partnership, OpenEvidence is set to collaborate directly with leading medical researchers in oncology, neuroscience, cardiology, and other specialties to further refine its AI-driven knowledge base. The platform is widely used during clinical hours, with 75% of physicians leveraging it at the point of care to inform decision-making.